Diagnostic Solutions Supporting the Battle Against COVID-19
Jun 09 2020
For decades, Tosoh Bioscience has enabled its biopharma partners to provide robust diagnostics solutions and safe and efficient therapies for life-threatening diseases. During the on-going battle against COVID-19, the necessary steps have been taken to ensure business continuity and to support the various R&D and production activities to combat the new Corona Virus.
In the diagnostics field, Tosoh is developing solutions for both detecting the SARS-CoV-2 RNA during acute infections and detecting antibodies specific to SARS-CoV-2 through serological tests in patients who symptomatically or asymptomatically contracted SARS-CoV-2. Tosoh Bioscience's chromatography experts are focusing their technological leadership on chromatography materials to support the development of methods for the analysis and industrial production of therapies, vaccines, and diagnostic solutions at their biotech and pharma customers.
Scientists worldwide are currently developing many vaccine and therapy projects using TOYOPEARL, TSKgel, and Ca++Pure-HA® chromatography media. The experience and reliability of Tosoh Bioscience ensure navigating safely through the clinical trials to launch biotherapeutics as fast as possible. The company listed several publications referring to vaccine development on a dedicated website on chromatographic solutions for COVID-19 vaccine development here.
Tosoh Bioscience ensures the availability of these products on a production scale throughout the crisis. It is, however, not enough to provide large volumes of chromatography media. The on-going race against Coronavirus makes it more evident than ever: scientists need to develop biotherapeutics and vaccines as fast as possible. Tosoh Bioscience launched SkillPak™ 1 and 5 mL pre-packed columns. These pre-packed chromatography columns provide a toolkit that supports fast purification method development.
The characterisation of monoclonal antibodies is crucial for both diagnostic and therapeutic applications. In diagnostics, antibodies are used to produce serological tests, and avoiding false-positives and false-negatives are key. This can only be achieved if the renowned test kit suppliers can be 100% sure of the quality of the antibodies. On the other hand, when producing antibodies for therapeutic applications, a precise characterisation is mandatory to avoid adverse effects, to increase the chances of successful clinical trials, and to ensure patient safety when going into production. Tosoh offers robust and reliable solutions for the analysis of antibodies at all these stages.
The separation of mAb monomers from their aggregates is one of the essential assays in mAb development and manufacturing. For decades, the TSKgel G3000SWXL size exclusion chromatography (SEC) column has been the gold standard for aggregate detection in the biopharmaceutical industry. Many scientists are developing their analytical methods during the current crisis using this well-known and robust HPLC column.
Tosoh Bioscience offers a variety of chromatography media and HPLC columns that can support the research, development, and production efforts in the fight against COVID-19. Moreover, they can speed-up the on-going development race through the pre-clinical, clinical, and production phases through their expertise.
Contact one of Tosoh’s chromatography experts to find out how their chromatography solutions can help you fight COVID-19.
In This Edition Articles - The challenges of Biosample access and what needs to change - Innovative UK exports must gather income - not dust Spotlight Life Sciences - How a Pipettin...
View all digital editions
Sep 27 2021 Virtual event
Sep 27 2021 Beijing, China
Sep 28 2021 Glasgow, Scotland
Sep 29 2021 Online event
Oct 03 2021 Prague, Czech Republic